Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

Gemcitabine‐based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second‐line treatment(s) established yet. Aberrant activation of the MAPK pathway in patients with BTC indicates its importance in BTC. Trametinib is a potent, highly selective, alloste...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Ikeda, Masafumi, Ioka, Tatsuya, Fukutomi, Akira, Morizane, Chigusa, Kasuga, Akiyoshi, Takahashi, Hideaki, Todaka, Akiko, Okusaka, Takuji, Creasy, Caretha L., Gorman, Shelby, Felitsky, Daniel J., Kobayashi, Mikiro, Zhang, Fanghong, Furuse, Junji
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765304/
https://ncbi.nlm.nih.gov/pubmed/29121415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13438
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados